Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for energy industry professionals · Tuesday, June 25, 2024 · 722,823,722 Articles · 3+ Million Readers

Global Potential Analysis of Human DNA Vaccines Market Size Worth USD 9,337 million by 2030 | CAGR of 9.5%

Potential Analysis of Human DNA Vaccines Market Trends 2024

Potential Analysis of Human DNA Vaccines Market Trends 2024

North America is expected to dominate the market & is projected to grow at the highest CAGR. Europe is the second-largest potential market

PORTLAND, OREGON, UNITED STATES, June 21, 2024 /EINPresswire.com/ -- According to a new report published by Allied Market Research, titled, Potential Analysis of Human DNA Vaccines Market by Forecast Scenario: Global Opportunity Analysis and Industry Forecast, 2020-2030, the global potential analysis of human DNA vaccines market is expected to account for $3,762 million by 2020 and reach $9,337 million by 2030, growing at a CAGR of 9.5% from 2020 to 2030. Key opportunities for market expansion include the high need for vaccines for immunization & prevention of infectious diseases.

The report provides an extensive analysis of changing market dynamics, major segments, value chain, competitive scenario, and regional landscape. This research offers a valuable guidance to leading players, investors, shareholders, and startups in devising strategies for sustainable growth and gaining competitive edge in the market.

๐–๐ก๐š๐ญ ๐š๐ซ๐ž ๐ญ๐ก๐ž ๐ƒ๐ซ๐ข๐ฏ๐ข๐ง๐  ๐…๐š๐œ๐ญ๐จ๐ซ๐ฌ ๐Ž๐Ÿ ๐๐จ๐ญ๐ž๐ง๐ญ๐ข๐š๐ฅ ๐€๐ง๐š๐ฅ๐ฒ๐ฌ๐ข๐ฌ ๐จ๐Ÿ ๐‡๐ฎ๐ฆ๐š๐ง ๐ƒ๐๐€ ๐•๐š๐œ๐œ๐ข๐ง๐ž๐ฌ ๐Œ๐š๐ซ๐ค๐ž๐ญ?

Increase in vulnerability of the population to infectious diseases and rise in number of antibiotics-resistant pathogens have created the need for effective and low-cost vaccination, which would provide long-lasting immunity. DNA vaccines have potential advantages over traditional methods, for example, low risk of infection, easy transportation, and stability at room temperature. The potential of global human DNA vaccines market is expected to be rapid, owing to property of DNA vaccines of specific antigen targeting, reduced risk of infection compared to conventional vaccines, and improved stability. Moreover, relative ease of large-scale manufacturing compared to traditional approach and low storage requirement are anticipated to be present few key market opportunities.

๐†๐ž๐ญ ๐…๐ฎ๐ฅ๐ฅ ๐๐ƒ๐… ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐‚๐จ๐ฉ๐ฒ ๐จ๐Ÿ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ (๐ˆ๐ง๐œ๐ฅ๐ฎ๐๐ข๐ง๐  ๐…๐ฎ๐ฅ๐ฅ ๐“๐Ž๐‚, ๐‹๐ข๐ฌ๐ญ ๐จ๐Ÿ ๐“๐š๐›๐ฅ๐ž๐ฌ & ๐…๐ข๐ ๐ฎ๐ซ๐ž๐ฌ, ๐‚๐ก๐š๐ซ๐ญ) ๐‚๐ฅ๐ข๐œ๐ค ๐‡๐ž๐ซ๐ž ๐ญ๐จ ๐ƒ๐จ๐ฐ๐ง๐ฅ๐จ๐š๐ ๐š ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ: https://www.alliedmarketresearch.com/request-sample/2309

๐“๐จ๐ฉ ๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ข๐ž๐ฌ ๐จ๐Ÿ ๐๐จ๐ญ๐ž๐ง๐ญ๐ข๐š๐ฅ ๐€๐ง๐š๐ฅ๐ฒ๐ฌ๐ข๐ฌ ๐จ๐Ÿ ๐‡๐ฎ๐ฆ๐š๐ง ๐ƒ๐๐€ ๐•๐š๐œ๐œ๐ข๐ง๐ž๐ฌ ๐Œ๐š๐ซ๐ค๐ž๐ญ

โ€ข Inovio Pharmaceuticals, Inc.
โ€ข GeneOne Life Science Inc.
โ€ข MedImmune, Immunomic Therapeutics, Inc.
โ€ข Astellas Pharma, Inc.
โ€ข Pharos Biologicals
โ€ข Sanofi S.A.
โ€ข F. Hoffmann-La Roche AG
โ€ข CureVac
โ€ข Boehringer Ingelheim GmbH.

๐๐จ๐ญ๐ž๐ง๐ญ๐ข๐š๐ฅ ๐€๐ง๐š๐ฅ๐ฒ๐ฌ๐ข๐ฌ ๐จ๐Ÿ ๐‡๐ฎ๐ฆ๐š๐ง ๐ƒ๐๐€ ๐•๐š๐œ๐œ๐ข๐ง๐ž๐ฌ ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐’๐ž๐ ๐ฆ๐ž๐ง๐ญ๐š๐ญ๐ข๐จ๐ง ๐œ๐š๐ง ๐›๐ž ๐๐จ๐ง๐ž ๐›๐š๐ฌ๐ž๐ ๐จ๐ง ๐ฌ๐ž๐ฏ๐ž๐ซ๐š๐ฅ ๐Ÿ๐š๐œ๐ญ๐จ๐ซ๐ฌ, ๐ข๐ง๐œ๐ฅ๐ฎ๐๐ข๐ง๐ :

By Product Type

โ€ข Prophylactic DNA Vaccines: Intended to prevent diseases, such as those for infectious diseases like influenza, HPV, and COVID-19.
โ€ข Therapeutic DNA Vaccines: Designed to treat existing conditions, including cancer and chronic infections.

2. By Technology

โ€ข Electroporation: A method to enhance DNA vaccine delivery by using electrical pulses to increase cell permeability.
โ€ข Gene Gun: A device that delivers DNA directly into cells using high-velocity microprojectiles.
โ€ข Jet Injection: A method that uses a high-pressure stream to deliver DNA vaccines through the skin.
โ€ข Liposome-based Delivery: Utilizes liposomes to encapsulate and deliver DNA into cells.
Nanoparticle-based Delivery: Employs nanoparticles to protect and deliver DNA to target cells.

3. By Application

โ€ข Infectious Diseases: Vaccines targeting viruses (e.g., HIV, HPV, influenza) and bacteria (e.g., tuberculosis).
โ€ข Cancer: Vaccines designed to treat various cancers, such as melanoma, prostate cancer, and breast cancer.
โ€ข Allergies: Vaccines aimed at reducing or eliminating allergic reactions.

4. By End User

โ€ข Hospitals: Facilities providing comprehensive healthcare services.
โ€ข Clinics: Outpatient settings offering vaccinations and treatments.
โ€ข Research Institutes: Organizations conducting clinical trials and research.
โ€ข Pharmaceutical and Biotechnology Companies: Companies developing, manufacturing, and commercializing DNA vaccines.

5. By Region

โ€ข North America: Includes the United States and Canada, with a focus on advanced healthcare infrastructure and high R&D investment.
โ€ข Europe: Comprising Western and Eastern Europe, with significant contributions from countries like Germany, France, and the UK.
โ€ข Asia-Pacific: Encompassing rapidly growing markets such as China, India, Japan, and Australia.
โ€ข Latin America: Including Brazil, Mexico, and other countries with emerging healthcare sectors.
โ€ข Middle East and Africa: Regions with varying degrees of market development and healthcare access.

6. By Distribution Channel

โ€ข Direct Sales: Sales made directly from manufacturers to end-users, such as hospitals and clinics.
โ€ข Distributors: Third-party entities that distribute vaccines to healthcare providers and facilities.
โ€ข Online Sales: Platforms facilitating the purchase of vaccines, primarily for research and professional use.

7. By Age Group

โ€ข Pediatrics: Vaccines developed for children and adolescents.
โ€ข Adults: Vaccines targeting the adult population, typically aged 18-65.
โ€ข Geriatrics: Vaccines designed for the elderly population, typically aged 65 and above.

Purchase the Report: https://www.alliedmarketresearch.com/purchase-enquiry/2309

๐Ž๐ฎ๐ซ ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐‘๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก ๐’๐จ๐ฅ๐ฎ๐ญ๐ข๐จ๐ง ๐๐ซ๐จ๐ฏ๐ข๐๐ž๐ฌ ๐˜๐จ๐ฎ ๐€๐ง๐ฌ๐ฐ๐ž๐ซ ๐ญ๐จ ๐๐ž๐ฅ๐จ๐ฐ ๐Œ๐ž๐ง๐ญ๐ข๐จ๐ง๐ž๐ ๐๐ฎ๐ž๐ฌ๐ญ๐ข๐จ๐ง:

โ€ข Which are the driving factors responsible for the growth of market?
โ€ข Which are the roadblock factors of this market?
โ€ข What are the new opportunities, by which market will grow in coming years?
โ€ข What are the trends of this market?
โ€ข Which are main factors responsible for new product launch?
โ€ข How big is the global & regional market in terms of revenue, sales and production?
โ€ข How far will the market grow in forecast period in terms of revenue, sales and production?
โ€ข Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
โ€ข How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
โ€ข Which region has more opportunities?

๐๐ฒ ๐‘๐ž๐ ๐ข๐จ๐ง ๐Ž๐ฎ๐ญ๐ฅ๐จ๐จ๐ค

โ€ข North America
(U.S., Canada, Mexico)
โ€ข Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
โ€ข Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
โ€ข LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

๐‚๐จ๐ง๐ญ๐š๐œ๐ญ ๐ƒ๐ž๐ญ๐š๐ข๐ฅ๐ฌ:

David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com

๐€๐›๐จ๐ฎ๐ญ ๐”๐ฌ

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โ€œMarket Research Reportsโ€ and โ€œBusiness Intelligence Solutions.โ€ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
X

Powered by EIN Presswire


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release